Arcturus Therapeutics Holdings Inc (ARCT)

Precedente Chiudi:

$27.91

Aprire:

$28

Volume 24 ore:

44,202

Capitalizzazione di mercato:

$751.56M

Reddito:

$157.75M

Utile/perdita netta:

$-29.73M

Rapporto P/E:

9.01

EPS:

2.99

Flusso di cassa netto:

$-21.00M

1 W Prestazione:

+3.13%

1M Prestazione:

-16.24%

6M Prestazione:

+45.02%

1 anno Prestazione:

+6.68%

Intervallo 1D:

$26.64

$28.14

Portata 52W:

$17.52

$43.81

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Nome

Arcturus Therapeutics Holdings Inc

Settore

Healthcare (1193)

Industria

Biotechnology (685)

Telefono

858-900-2660

Indirizzo

10628 Science Center Drive, Suite 250, San Diego, CA

Dipendente

60

Cinguettio

@ArcturusRx

Prossima data di guadagno

2024-05-08

Ultimi documenti SEC

ARCT's Discussions on Twitter

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-07-24	Iniziato	William Blair	Outperform
2023-05-11	Aggiornamento	H.C. Wainwright	Neutral → Buy
2022-11-14	Ripresa	Wells Fargo	Overweight
2022-11-10	Downgrade	Robert W. Baird	Neutral → Underperform
2022-11-03	Aggiornamento	Citigroup	Neutral → Buy
2022-11-02	Aggiornamento	Barclays	Underweight → Equal Weight
2022-08-10	Downgrade	Raymond James	Mkt Perform → Underperform
2022-07-19	Ripresa	Cantor Fitzgerald	Overweight
2022-05-11	Aggiornamento	Robert W. Baird	Underperform → Neutral
2022-04-21	Downgrade	Citigroup	Buy → Neutral
2022-01-31	Aggiornamento	Raymond James	Underperform → Mkt Perform
2021-08-12	Downgrade	Raymond James	Mkt Perform → Underperform
2021-08-11	Downgrade	Goldman	Neutral → Sell
2021-08-10	Downgrade	Robert W. Baird	Neutral → Underperform
2021-07-02	Iniziato	Cantor Fitzgerald	Overweight
2021-06-25	Ripresa	Goldman	Neutral
2021-06-21	Downgrade	Barclays	Equal Weight → Underweight
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-02-17	Downgrade	B. Riley Securities	Neutral → Sell
2021-01-19	Downgrade	B. Riley Securities	Buy → Neutral
2021-01-15	Downgrade	B. Riley Securities	Buy → Neutral
2021-01-07	Iniziato	Wells Fargo	Overweight
2020-12-29	Downgrade	Barclays	Overweight → Equal Weight
2020-12-29	Downgrade	H.C. Wainwright	Buy → Neutral
2020-12-29	Downgrade	Raymond James	Outperform → Mkt Perform
2020-12-29	Downgrade	Robert W. Baird	Outperform → Neutral
2020-12-23	Downgrade	ROTH Capital	Buy → Sell
2020-12-08	Reiterato	B. Riley Securities	Buy
2020-12-07	Reiterato	B. Riley Securities	Buy
2020-10-26	Iniziato	Barclays	Overweight
2020-10-06	Iniziato	Citigroup	Buy
2020-08-26	Iniziato	Piper Sandler	Overweight
2020-07-30	Ripresa	ROTH Capital	Buy
2020-07-16	Iniziato	Raymond James	Outperform
2020-07-13	Iniziato	B. Riley FBR	Buy
2020-06-09	Downgrade	WBB Securities	Buy → Hold
2020-02-11	Iniziato	Robert W. Baird	Outperform
2020-02-07	Iniziato	Guggenheim	Buy
2020-02-06	Iniziato	Guggenheim	Buy
2019-04-05	Iniziato	H.C. Wainwright	Buy
2018-09-20	Aggiornamento	WBB Securities	Buy → Strong Buy
2018-01-22	Iniziato	Chardan Capital Markets	Buy

Mostra tutto

Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie

Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts

Benzinga

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Zacks Investment Research

Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga

Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

Benzinga

Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari

Arcturus Therapeutics Holdings Inc (ARCT) Reddito 2024

Arcturus Therapeutics Holdings Inc (ARCT) Reddito netto 2024

Arcturus Therapeutics Holdings Inc (ARCT) Flusso di cassa 2024

Arcturus Therapeutics Holdings Inc (ARCT) Utile per azione 2024